Skip to main content
. Author manuscript; available in PMC: 2011 Sep 1.
Published in final edited form as: Neuropharmacology. 2010 Apr 22;59(4-5):353–357. doi: 10.1016/j.neuropharm.2010.03.011

Table 1. Increased scyllo-inositol in frontal cortex and hippocampus in triple transgene mice using HRMAS.

Chemical/Cr Frontal Cortex Hippocampus
Scyllo (n=5) Reg (n=3) Scyllo (n=7) Reg (n=7)
GABA 0.306±.041 0.362±.138 0.356±.157 0.315±.053
Acetate 0.033±.009 0.039±.006 0.049±.017 0.053±.022
Alanine 0.075±.008 0.084±.007 0.060±.019 0.066±.013
Aspartate 0.350±.037 0.317±.080 0.366±.082 0.334±.042
Choline 0.286±.034 0.258±.043 0.171±.049 0.196±.076
Glutamate 1.132±.135 1.106±.099 0.667±.114 0.679±.063
Glutamine 0.360±.060 0.394±.053 0.458±.107 0.368±.031
Glycine 0.116±.017 0.112±.004 0.131±.023 0.134±.025
Lactate 0.806±.081 0.689±.055 0.961±.183 0.819±.228
NAA 0.825±.069 0.796±.075 0.534±.067 0.485±.078
Scyllo-Inositol 0.035±.008* 0.016±.003 0.074±.018* 0.031±.011
Taurine 1.580±.215 1.553±.277 1.07±.230 0.986±.133
myo-Inositol 0.736±.112 0.759±.170 0.701±.110 0.748±.114

Concentrations reported as molar ratios to creatine.

Errors reported are standard deviations.

*

p<0.001; t-test corrected for multiple comparisons